Immune profile testing in women with long-lasting pelvic pain not helped by first treatments
Tests an immune response test in women with endometriosis or chronic pelvic pain.
Plain-language title generated from the registry record
Registry title: Identify a Specific Immune Profile in Patients With Chronic Pelvic Pain Resistant to First-line Treatments by Measuring Th1, Th2, Th17, and Treg Cytokines Produced After Non-specific Functional Cell Stimulation - ImmunoCPP
Key facts
- Where
- Nice, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
Source: NCT07429773, who can take part
Where in France
- CHU Nice - Hopital de l Archet 2Nice, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire de Nice
- Trial code
- NCT07429773
- Record updated
- 27 July 2026
- Original description
Chronic pelvic pain (CPP) affects more than one in four women. An immune imbalance in the Th1/Th2 balance has been reported in multiple CPP situations, particularly in patients with endometriosis, but with mixed results. The use of a functional immune test, already validated in previous indications and particularly in infertility, could simulate an immune stimulation similar to that of painful attacks.Read full original descriptionShow less
Identify a Specific Immune Profile in Patients With Chronic Pelvic Pain Resistant to First-line Treatments by Measuring Th1, Th2, Th17, and Treg Cytokines Produced After Non-specific Functional Cell Stimulation - ImmunoCPP
Chronic pelvic pain (CPP) affects more than one in four women. An immune imbalance in the Th1/Th2 balance has been reported in multiple CPP situations, particularly in patients with endometriosis, but with mixed results. The use of a functional immune test, already validated in previous indications and particularly in infertility, could simulate an immune stimulation similar to that of painful attacks.
Inclusion: Aged between 18 and 40; Under continuous hormone treatment for at least 6 months; Imaging less than 12 months old: either normal or showing endometriosis and/or adenomyosis lesions, excluding any other abnormalities that could explain the PCOS; Affiliation with the French Social Security system; Signature of informed consent.
Exclusion: Autoimmune disease; History of cancer within the last 5 years or currently undergoing treatment; Current infectious syndrome; Pregnant or breastfeeding women; Person under guardianship or conservatorship.